Population pharmacokinetic modelling to characterize the effect of chronic kidney disease on tenofovir exposure after tenofovir alafenamide administration

BACKGROUND: Tenofovir alafenamide is gradually replacing tenofovir disoproxil fumarate, both prodrugs of tenofovir, in HIV prevention and treatment. There is thus an interest in describing tenofovir pharmacokinetics (PK) and its variability in people living with HIV (PLWH) under tenofovir alafenamid...

Descripción completa

Detalles Bibliográficos
Autores principales: Thoueille, Paul, Alves Saldanha, Susana, Desfontaine, Vincent, Kusejko, Katharina, Courlet, Perrine, Andre, Pascal, Cavassini, Matthias, Decosterd, Laurent A, Buclin, Thierry, Guidi, Monia
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2023
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10232258/
https://www.ncbi.nlm.nih.gov/pubmed/37042359
http://dx.doi.org/10.1093/jac/dkad103

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10232258/
https://www.ncbi.nlm.nih.gov/pubmed/37042359
http://dx.doi.org/10.1093/jac/dkad103

Ejemplares similares